SCHEMBL6795402

SCHEMBL6795402

Cc1ccc(C2CCN(CCCC(=O)Nc3ccccc3C(N)=O)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.56
HTR7 P34969 3/20 0.56
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HDAC1 Q13547 1/20 0.50
DRD4 P21917 4/20 0.49
DRD2 P14416 3/20 0.49
DRD3 P35462 3/20 0.49
ALDH1A1 P00352 2/20 0.49
ADRA1D P25100 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KDM4E B2RXH2 1/20 0.47
PRMT5 O14744 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6802419 0.91 HTR7 (0.57) HTR1AHTR7CYP3A4CYP2D6CYP2C9
SCHEMBL6795772 0.89 HTR1A (0.53) HTR1AHTR7CYP3A4CYP2D6CYP2C9
SCHEMBL6795910 0.88 HTR7 (0.53) HTR1AHTR7CYP3A4CYP2D6CYP2C9
SCHEMBL6794897 0.86 HTR7 (0.53) HTR1AHTR7CYP3A4CYP2D6CYP2C9
SCHEMBL7957652 0.81 DRD2 (0.55) DRD4DRD2DRD3ALDH1A1ADRA1D
SCHEMBL9070717 0.77 ADRA1D (0.65) HTR1AHTR7CYP2D6CYP2C19DRD4
SCHEMBL6798006 0.76 HTR1A (0.75) HTR1AHTR7ALDH1A1KMT2AKDM4E
SCHEMBL11007751 0.76 POLB (0.59) HTR1AHTR7CYP3A4CYP2D6CYP2C19
SCHEMBL12946163 0.75 HTR1A (0.58) HTR1AHTR7ALDH1A1MEN1KMT2A
SCHEMBL11465879 0.74 CARM1 (0.54) HTR7CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077667-A1 Quinazolinone derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-22 US disclosed
EP-1355888-A1 QUINAZOLINONE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-10-29 EP disclosed
WO-2002048117-A1 QUINAZOLINONE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077667-A1 Quinazolinone derivatives PARP1, PARP9, PARP2 HTR1A 848/4885HTR7 1045/4885CYP3A4 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.